FDA Tentatively Approves Generic Enzalutamide for Prostate Cancer

The U.S. FDA has granted tentative approval for a generic version of enzalutamide tablets, a treatment for advanced prostate cancer. This decision could pave the way for increased access to this androgen receptor pathway inhibitor once exclusivity protections expire. Notably, the approval includes new strengths not currently available for the branded product.